Assessing the landscape of tools and approaches for novel tuberculosis regimen development.

Abstract

Keywords. tuberculosis; drug-resistant tuberculosis; pharmacokinetics; pharmacodynamics; animal model. In 2011, the Critical Path to TB Drug Regimens (CPTR) initiative, a broad-reaching collaboration among industry, academia, government, regulatory, and nonprofit organizations, was formed with the vision to support innovations in antituberculosis drug development. The CPTR program, led by the Bill & Melinda Gates Foundation, Tuberculosis Alliance and Critical Path Institute, is keenly focused on the accelerated delivery of safer, more efficacious, and faster-acting tuberculosis regimens by developing and promoting innovative regu